Drug Distribution Articles & Analysis
18 articles found
Precise and safe delivery of drugs to target sites has always been an important task for researchers in modern medicine. With the development of nanotechnology, a variety of nanodrug delivery systems (NDDS) have been designed and prepared, such as the most familiar liposomes, polymer nanoparticles, and metal nanoparticles. However, a new kind of drug delivery system has also gradually emerged in ...
The evolution of 3D printing technology has opened up new avenues in the pharmaceutical industry, especially in the fabrication of novel drug delivery systems. One such advancement is the 3D printing of Oral Thin Films (OTFs), which are ultra-thin films used to deliver drugs via oral mucosa. Unlike traditional methods, 3D printing allows the precise layering of active pharmaceutical ingredients ...
Pharmacokinetics (PK) and pharmacodynamics (PD) are two fundamental pillars in the field of pharmacology and drug development. Understanding their intricate interplay is essential for determining the efficacy and safety of therapeutic compounds. When studied in living organisms, this relationship is referred to as in vivo PK/PD, a discipline that provides invaluable insights into drug behavior ...
The scientific realm behind the development and evaluation of therapeutic drugs, pesticides, industrial and environmental chemicals profoundly relies on a field of research called Pharmacokinetic/Toxicokinetic (PK/TK) studies. These investigations provide substantial information on how an organism affects a substance, delineating vital zones of absorption, distribution, metabolism, and excretion. ...
Therapeutic monoclonal antibodies (mAbs) are a class of antibody drugs that are highly uniform and have pharmacological effects against a single epitope obtained through molecular biology. In the process of new drug development, the study of pharmacokinetics is of great significance. The result can be used to guide the screening and development of drugs, and support the evaluation of their ...
Since antibody-drug conjugates (ADCs) have the molecular characteristics of both small molecule and macromolecule therapeutic drugs, when choosing analytical methods, the typical ones used for both should all be considered. There are many different molecules in ADCs, and the difference between these molecules lies in the drug-to-antibody ratio (DAR) value and/or the site where the antibody binds ...
In order to more effectively deliver chemotherapy drugs, Small Molecule Drug Conjugates (SMDC), Antibody Drug Conjugates (ADC), and Degradation Antibody Conjugates (DAC) have been successively explored and developed, enhancing the therapeutic index while providing selective delivery. What are their similarities and differences? What are their respective advantages? What is the current status of ...
Drug development is a complex and multifaceted process that involves extensive research and testing to ensure safety, efficacy and quality for human use. One critical element in the drug development process is drug metabolism and pharmacokinetics (DMPK), which refers to how a drug is absorbed, distributed, metabolized, and excreted (ADME) from the body. In vitro DMPK services, along with ...
Antibody drug conjugates (ADCs) are a new class of biopharmaceuticals that use monoclonal antibodies to target tumor cells to deliver potent cytotoxic drugs. So far, a total of 15 ADC drugs have been approved worldwide, of which the FDA has approved 13 ADCs for various cancers, including Adcetris®, Kadcyla®, Besponsa®, Mylotarg®, Lumoxiti®, Polivy®, Padcev®, Enhertu ®, Trodelvy® and Blenrep®. As ...
Drug development is a complex and multifaceted process that involves extensive research and testing to ensure safety, efficacy and quality for human use. One critical element in the drug development process is drug metabolism and pharmacokinetics (DMPK), which refers to how a drug is absorbed, distributed, metabolized, and excreted (ADME) from the body. In vitro DMPK services, along with ...
Nano-vesicles, also known as liposomes, have emerged as promising drug delivery systems due to their unique structure and properties. These tiny spherical lipid bilayers can encapsulate various therapeutic agents, including protein drugs. In this article, we will explore the process of preparing nano-vesicles for encapsulating protein drugs, as well as the advantages of utilizing this innovative ...
In recent years, bioconjugation has emerged as a powerful strategy for improving drug delivery and enhancing therapeutic efficacy. By linking drugs to various biological entities, such as proteins, antibodies, nanoparticles, or targeting moieties, bioconjugation enables precise and targeted delivery of therapeutic agents to desired sites. This article aims to provide an overview of different ...
In the world of pharmaceuticals, developing safe and effective drugs is a complex and time-consuming process. Before a new drug candidate can progress to clinical trials and ultimately reach the market, it needs to undergo rigorous testing in various model systems to assess its efficacy and safety. One critical component of this evaluation is the use of preclinical animal models. Preclinical ...
Average drug-to-antibody ratio (DAR) and drug load distribution are two vital properties of antibody drug conjugates (ADCs). Over the years, several ADC bioanalytical methods have been developed to better estimate these properties for early development and routine quality control applications. In this article, we provide an overview of the most widely used methods for the detailed analysis of DAR ...
Prediction of the first-in-human dosing regimens is a critical step in drug development and requires accurate quantitation of drug distribution. Traditional in vivo studies used to characterize clinical candidate’s volume of distribution are error-prone, time and cost intensive and lack reproducibility in clinical settings. The paper demonstrates how a computational platform integrating ...
The Drug Supply Chain Security Act (DSCSA) is Title II of the Drug Quality and Security Act (DQSA) and is designed to protect consumers from potentially harmful drugs. New requirements roll out on November 27th of each year. Each new requirement progresses toward building an electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the United ...
The Drug Supply Chain Security Act (DSCSA) is Title II of the Drug Quality and Security Act (DQSA), which was enacted to enhance FDA’s ability to protect consumers from exposure to potentially harmful drugs. The act outlines steps to build an electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the United States. New requirements ...
Many hospitals struggle to achieve optimal compliance with the Drug Supply Chain Security Act (DSCSA). The challenge to comply seems to come from an incomplete or inaccurate understanding of the regulations, which is understandable given the Act’s complexity. DSCSA was put in place to protect consumers from harmful drugs, such as those that are stolen or contaminated. The Act outlines ...